Published on 20.03.17 in Vol 6, No 3 (2017): March
Works citing "Use of the Total Cancer Care System to Enrich Screening for CD30-Positive Solid Tumors for Patient Enrollment Into a Brentuximab Vedotin Clinical Trial: A Pilot Study to Evaluate Feasibility"
According to Crossref, the following articles are citing this article (DOI 10.2196/resprot.7289):
(note that this is only a small subset of citations)
-
Sharman JP, Wheler JJ, Einhorn L, Dowlati A, Shapiro GI, Hilton J, Burke JM, Siddiqi T, Whiting N, Jalal SI. A phase 2, open-label study of brentuximab vedotin in patients with CD30-expressing solid tumors. Investigational New Drugs 2019;37(4):738
CrossRef -
Xu ML, Gabali A, Hsi ED, Fedoriw Y, Vij K, Salama ME, Ramchandren R, O’Malley D, Wick MR, Battistella M, Gru AA. Practical Approaches on CD30 Detection and Reporting in Lymphoma Diagnosis. American Journal of Surgical Pathology 2020;44(2):e1
CrossRef -
. Clinical Decision Support Tools Improving Cancer Care. Seminars in Oncology Nursing 2018;34(2):158
CrossRef -
Dalton WS, Sullivan D, Ecsedy J, Caligiuri MA. Patient Enrichment for Precision‐Based Cancer Clinical Trials: Using Prospective Cohort Surveillance as an Approach to Improve Clinical Trials. Clinical Pharmacology & Therapeutics 2018;104(1):23
CrossRef -
Nassif S, El-Zaatari ZM, Attieh M, Hijazi M, Fakhreddin N, Aridi T, Boulos F. Lack of expression of ALK and CD30 in breast carcinoma by immunohistochemistry irrespective of tumor characteristics. Medicine 2019;98(32):e16702
CrossRef
According to Crossref, the following books are citing this article (DOI 10.2196/resprot.7289):
-
Lin TA, Eroglu Z, Carvajal R, Markowitz J. Translational Bioinformatics for Therapeutic Development. 2021. Chapter 3:35
CrossRef